Press Releases
CAS Medical Systems, Inc. Reports Placement of 50th FORE-SIGHT® Cerebral Oximeter - FORE-SIGHT Included in NIH-Funded Multi-Center Study
- Cerebral Oximetry Added to STS National Database
Branford, CT – February 6, 2008 – CAS Medical Systems, Inc. (NASDAQ: CASM), a medical device company focused on innovative, non-invasive vital signs monitoring, today announced the placement of its fiftieth revenue-generating FORE-SIGHT monitor in North America. The FORE-SIGHT monitor, which non-invasively and continuously measures absolute cerebral tissue oxygen saturation, was commercially introduced mid-2007. Andrew E. Kersey, President and CEO of CASMED, commented, “Reaching the milestone of the 50th unit is an important indication of our initial success in penetrating the cerebral oximetry market. These placements represent over twenty institutions in North America, all of which are generating income from sales of sensors. In addition, a number of monitors are in the field undergoing clinical evaluations by customers as we continue to see strong interest in the FORE-SIGHT solution. We have made significant inroads both with customers who are new to cerebral oximetry, and with past users of cerebral oximetry, who have moved to our technology based on their recognition of the importance of the absolute saturation values provided by CASMED’s advanced LASER-SIGHT® Optical Technology.” The Company reports that clinical studies are on-going at various locations throughout North America. For the adult population, studies targeting aortic, thoracic, orthopedic and general surgeries are underway. Enrollment for the 60 patient CABG surgery study at Duke University Medical Center is now complete and results from this study are expected later this year. Additionally, the Company is participating in a new NIH-funded major multi-center study researching cognitive decline and delirium in elderly patients undergoing major general surgery. Customer preference testing is also underway at five key infant / neonatal clinical locations throughout the US to support the launch of the infant / neonatal sensor later this year. In Europe, we are planning to complement the FORE-SIGHT product launch by establishing two adult clinical research / reference sites. The Company also announced the acceptance for publication of a cerebral oximetry review paper to be published in Seminars in Cardiothoracic and Vascular Anesthesia. The publication, entitled “Recent Advances in the Application of Cerebral Oximetry in Adult Cardiovascular Surgery”, was authored by Gregory W. Fischer, M.D., Co-Director of Cardiac Anesthesia at Mount Sinai Medical Center in New York. It reviews the development of cerebral oximetry technology, and evaluates his experience with currently available monitoring devices. In addition, CASMED reports that FORE-SIGHT has received considerable attention at the Society of Thoracic Surgeons (STS) meeting in Fort Lauderdale, Florida this week. Beginning last month, the STS National Database of outcomes in the areas of adult cardiac, general thoracic and congenital surgeries will be including cerebral oximetry measurements as part of their metrics. The Company believes that the inclusion of cerebral oximetry in this database elevates the importance and general awareness of the parameter and forwards the efforts to make cerebral oximetry monitoring a standard of care in these surgical cases. About the FORE-SIGHT Absolute Cerebral Oximeter About CASMED® For further information regarding CAS Medical Systems, Inc., visit the Company’s website at www.casmed.com. Company Contacts Director of Corporate Communications |
